https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901053-X/fulltext
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA - The Lancet